2020
DOI: 10.2139/ssrn.3569837
|View full text |Cite
|
Sign up to set email alerts
|

Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
25
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 16 publications
(25 citation statements)
references
References 25 publications
0
25
0
Order By: Relevance
“…Two of us (SC and ADC) independently reviewed the studies identified, then jointly excluded the articles not adhering to one or both criteria, and agreed on a final selection of 18 studies [7,8,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]. Findings from the CORIST project presented in this manuscript were also included in the meta-analyses, for a total of 19 studies.…”
Section: Methods Used For the Meta-analysismentioning
confidence: 99%
See 1 more Smart Citation
“…Two of us (SC and ADC) independently reviewed the studies identified, then jointly excluded the articles not adhering to one or both criteria, and agreed on a final selection of 18 studies [7,8,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]. Findings from the CORIST project presented in this manuscript were also included in the meta-analyses, for a total of 19 studies.…”
Section: Methods Used For the Meta-analysismentioning
confidence: 99%
“…ǂ Lopinavir, darunavir, tocilizumab, sarilumab, corticosteroids or remdesivir considered as a unique group, missing data for N = 237 patients. [17,22,25,26]. The exposure to either ACE-I or ARB was analyzed separately or in combination, and was tested for association with mortality or a combined outcome of severe illness and mortality (Online Supplement Table 1).…”
Section: Tablementioning
confidence: 99%
“…The characteristics of the shortlisted studies are summarized in Table 1. Among shortlisted studies, 23 studies were from China , nine studies were from Italy [64][65][66][67][68][69][70][71][72], ten studies were from the United States [83][84][85][86][87][88][89][90][91][92], four studies were from South Korea [75][76][77][78], three studies were from France [60][61][62], two studies were from Spain [79,80], one study each was from Belgium [35], Denmark [59], Hong Kong [63], Kuwait [73], Singapore [74], Turkey [81], and the United Kingdom [82]; and one study included data from 38 countries [93]. There were 24 studies that included hypertensive patients exclusively (100%) [36, 38, 39, 43-45, 47, 48, 50-52, 54, 56, 58, 66, 71, 72, 75, 78, 81, 87-89, 91].…”
Section: Characteristics Of the Included Studiesmentioning
confidence: 99%
“…2; pooled OR = 0.73, 95% CI 0.56-0.95). In a separate pooled analysis of 11 studies that provided adjusted HRs, with 26,598 COVID-19 patients being analyzed [36,54,56,57,59,67,69,70,72,74,77], the use of an ACEI/ARB was significantly associated with lower risk of mortality compared to the non-use of an ACEI/ARB (Supplementary Figure S1; pooled HR = 0.75, 95% CI 0.60-0.95). The funnel plot was used to detect the publication bias and revealed some degree of asymmetry (Supplementary Figure S3 and S4).…”
Section: Characteristics Of the Included Studiesmentioning
confidence: 99%
“…After screening 343 citations, 13 observational studies were included (Figure 1) [18][19][20][21][22][23][24][25][26][27][28][29][30], combining to a total sample of 14,364 participants. The characteristics of included studies are summarized in Table 1.…”
Section: Resultsmentioning
confidence: 99%